nach oben

The European Journal of Health Economics

Erschienen in:

01.06.2007 | Discussion

Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi

verfasst von: Joshua Cohen

Erschienen in: The European Journal of Health Economics | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Excerpt

In their editorial, Garattini and Ghislandi (GG) suggest we should not necessarily worry about non-launches and launch delays of new chemical entities (NCEs) that could be attributed to price controls [1]. GG direct their comments at Danzon et al. [2]. …

Garatinni, L., Ghislandi, S.: Should we really worry about “launch delays” of new drugs in OECD countries?” Eur. J. Health Econ. 8, 1–3 (2007)CrossRef

Danzon, P., Wang, M., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from twenty five major markets in the 1990s. Health Econ. 14, 269–295 (2005)CrossRef

Cohen, J., Faden, L., Predaris, S., Young, B.: Patient access to pharmaceuticals: an international comparison. Eur. J. Health Econ. (2007) http://dx.doi.org/10.1007/s10198-006-0028-z

Devlin, N., Parkin, D.: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 13(5), 437–452 (2004)CrossRef

Jonsson, B., Wilking, N.: A pan-European comparison of patient access to cancer medications. See http://ki.se/content/1/c4/33/52/Cancer_Report.pdf. Accessed 11 March (2007)

Titel: Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
verfasst von: Joshua Cohen
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 2/2007
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-007-0055-4

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Pharmacoeconomic studies in Italy: a critical review of the literature

The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience

Patients’ willingness to pay for electronic communication with their general practitioner

An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany

Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain